3C – CAMBRIDGE | CMC | CDMO

Maximizing Value From An Early Stage

11 June 2026
10:30 – 15:30

3C is jointly organised by:

nanoform
small is powerful®

pharmagro
WE MANAGE MOLECULE UNCERTAINTY

This inaugural event will focus on the importance of putting in place a value-creating CMC (Chemistry, Manufacturing, Control) Strategy. It brings together start-ups and established pharma companies, CMC consultants and Contract Manufacturing & Development Organisations. CMC now has a huge impact on the ability to scale, manufacture and ultimately on exit valuations.

Agenda

- Introduction – Nick Wigdahl & Christian Jones
- The Value of Getting CMC Right for a Small Biotech - Fireside Chat with Matthew Fyfe, CSO Outrun Therapeutics:
- Small Molecule Drug Substance CMC – Phase Appropriate Challenges and Opportunities - Dr John Knight, JKONSULT
- Scaling and Optimising Small Molecule and Biologic Drug Substances - Mark Walsh, Director, APC
- Maximising CMC Value in Small Molecule and Biologic Drug Products - Christian Jones, CCO, Nanoform
- Due Diligence - From A Large Pharma Perspective - Dr Kurt Pike, J&J Innovative Medicines
- Round Table: CDMO, CMC, Pharma
- Wrap-Up – Next Steps – Resources

Nick Wigdahl – CEO
Pharmagro provides software and services for Business Development and Portfolio Management to Life Science Companies and CDMOs. Power-Up your BD, optimise your portfolio.
ww.pharmagro.co.uk

Christian Jones – CCO
Nanoform improve the performance of your small- and large-molecule formulations by enabling higher drug loads in smaller tablets, in subcutaneous injections, and alternative delivery formats.
www.nanoform.com

Invitation only. Members of Innovate Cambridge, who represent one of the 3 Cs, are welcome. Location 100 Hills Road, Cambridge, CB2 1AR
Coffee and Lunch will be provided
To register your interest please scan the QR code